Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular
- PDF / 774,779 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 10 Downloads / 209 Views
ORIGINAL ARTICLE
Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma Kojiro Hata1,2 · Kimitaka Suetsugu1 · Nobuaki Egashira1,2 · Yoko Makihara1 · Shinji Itoh3 · Tomoharu Yoshizumi3 · Masatake Tanaka4 · Motoyuki Kohjima5 · Hiroyuki Watanabe1 · Satohiro Masuda6,7 · Ichiro Ieiri1 Received: 28 July 2020 / Accepted: 10 October 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose This study aimed to examine the association between the trough plasma concentration of lenvatinib with the objective response rate (ORR) and adverse events in patients with hepatocellular carcinoma (HCC). Methods Twenty-one patients with HCC who received lenvatinib were enrolled. We examined the median trough concentration (Ctrough median) of plasma lenvatinib until the first clinical response evaluation. The receiver-operating characteristic curve was drawn to show the discrimination potential of the C trough median for the ORR, using the modified Response Evaluation Criteria in Solid Tumors. Adverse events were graded based on the Common Terminology Criteria for Adverse Events (ver. 5.0). Results The Ctrough median values in the complete response and partial response group were significantly higher than those in the stable disease and progressive disease groups. The ORR was significantly higher in the high-C trough median group (≥ 42.68 ng/mL) than in the low-Ctrough median group (
Data Loading...
